Year 2022 / Volume 114 / Number 6
Submission and tracking of manuscripts
Instructions to authors

Submission and tracking

REED Journal

REED Journal

Play video

Year 2022 / Volume 114 / Number 6

Letter

Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury

356-357

Flor M. Fernández-Gordón Sánchez, Elena Gómez-Domínguez, Diana Paredes Ruiz, Yolanda Rodríguez Gil, Ana Martín Algíbez, Inmaculada Fernández Vázquez, Pilar Martínez Montiel,

Pembrolizumab, a programmed cell death receptor (PD-1) inhibitor, have improved the prognosis in several types of cancer. Despite the important clinical benefits, checkpoint inhibition have been associated with inflammatory and immune-related side effects (irAE).

Reader rating: Rate this article:
Share Button
Send by e-mail

New comment


Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comments

No hay comentarios para este artículo.
Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
© 2022 The Spanish Journal of Gastroenterology